Switch theme
Sign up to access all valuation multiples
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
2012
88
LTM Revenue $3.2M
LTM EBITDA -$9.1M
$35.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Molecure has a last 12-month revenue (LTM) of $3.2M and a last 12-month EBITDA of -$9.1M.
In the most recent fiscal year, Molecure achieved revenue of n/a and an EBITDA of -$7.5M.
Molecure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Molecure valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | -$0.9M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$9.1M | XXX | -$7.5M | XXX | XXX | XXX |
| EBITDA Margin | -284% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$9.9M | XXX | -$8.9M | XXX | XXX | XXX |
| EBIT Margin | -307% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$9.7M | XXX | -$8.6M | XXX | XXX | XXX |
| Net Margin | -303% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Molecure's stock price is PLN 8 (or $2).
Molecure has current market cap of PLN 163M (or $44.7M), and EV of PLN 129M (or $35.4M).
See Molecure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35.4M | $44.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Molecure has market cap of $44.7M and EV of $35.4M.
Molecure's trades at 1287986.2x EV/Revenue multiple, and -4.7x EV/EBITDA.
Equity research analysts estimate Molecure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Molecure has a P/E ratio of -4.6x.
See valuation multiples for Molecure and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $44.7M | XXX | $44.7M | XXX | XXX | XXX |
| EV (current) | $35.4M | XXX | $35.4M | XXX | XXX | XXX |
| EV/Revenue | 11.0x | XXX | 1287986.2x | XXX | XXX | XXX |
| EV/EBITDA | -3.9x | XXX | -4.7x | XXX | XXX | XXX |
| EV/EBIT | -3.6x | XXX | -4.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.6x | XXX | -5.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMolecure's last 12 month revenue growth is -35%
Molecure's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.1M for the same period.
Molecure's rule of 40 is -16455086% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Molecure's rule of X is -372% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Molecure and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -35% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -284% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -16% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -16455086% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -372% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Molecure acquired XXX companies to date.
Last acquisition by Molecure was XXXXXXXX, XXXXX XXXXX XXXXXX . Molecure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Molecure founded? | Molecure was founded in 2012. |
| Where is Molecure headquartered? | Molecure is headquartered in Poland. |
| How many employees does Molecure have? | As of today, Molecure has 88 employees. |
| Is Molecure publicy listed? | Yes, Molecure is a public company listed on WAR. |
| What is the stock symbol of Molecure? | Molecure trades under MOC ticker. |
| When did Molecure go public? | Molecure went public in 2018. |
| Who are competitors of Molecure? | Similar companies to Molecure include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Molecure? | Molecure's current market cap is $44.7M |
| What is the current revenue of Molecure? | Molecure's last 12 months revenue is $3.2M. |
| What is the current revenue growth of Molecure? | Molecure revenue growth (NTM/LTM) is -35%. |
| What is the current EV/Revenue multiple of Molecure? | Current revenue multiple of Molecure is 11.0x. |
| Is Molecure profitable? | Yes, Molecure is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Molecure? | Molecure's last 12 months EBITDA is -$9.1M. |
| What is Molecure's EBITDA margin? | Molecure's last 12 months EBITDA margin is -284%. |
| What is the current EV/EBITDA multiple of Molecure? | Current EBITDA multiple of Molecure is -3.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
